The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.
To deliver large proteins past the blood-brain barrier for the treatment of Alzheimer's, researchers have developed a compound that acts as a molecular "crossing guard" for drugs to safely target brain cells and clear plaques believed to cause symptoms of the disease.
The pharma giant is recruiting new patients while expanding the program with a new Phase III study for early-stage patients--without changing the dosing regimen.
Researchers at the Karolinska Institutet in Sweden have shown that omega-3 fatty acids can cross the blood-brain barrier in a potential treatment for Alzheimer's disease.
There may be a new way to diagnose whether a patient is progressing toward dementia/Alzheimer's or experiencing more benign, age-related memory loss. It amounts to a revamped approach toward analyzing the results of cognitive tests.
The hunt for new biomarkers that can help guide the diagnosis and, eventually, some method of treatment for Alzheimer's has spurred Big Pharma and non-profit groups to fund a careful investigation into the disease's links to Down syndrome.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
Researchers at Johns Hopkins say they've been able to track a pair of biomarkers that can shed light on a patient's risk of developing Alzheimer's and pinpoint the disease before telltale symptoms appear.
A newly identified set of microRNAs may give scientists fresh insight into how protein levels in the brains of Alzheimer's patients are regulated.